Aclarion, Inc. - SIC # 3840 -

Ticker Exchange SIC # Website Latest Ticker
ACON Nasdaq 3840 www.aclarion.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Aclarion, Inc.

Aclarion, Inc. (ACON) Reports Q1 Loss, Misses Revenue Estimates - May 13th, 2026 4:10 pm
Natera (NTRA) Reports Q1 Loss, Tops Revenue Estimates - May 7th, 2026 5:05 pm
Aclarion Announces Addition of First Private Practice Site in Los Angeles into CLARITY Trial to Further Accelerate Enrollment - May 7th, 2026 4:00 am
Aclarion Announces Inducement Grant to New Commercial Director, Western U.S. - May 6th, 2026 4:00 am
Aclarion Announces Second Commercial Agreement with Weill Cornell Medicine - May 5th, 2026 4:00 am
Aclarion Delivers Strong Q1 2026 Results with 196% Annual Scan Volume Growth Reflecting Accelerating Clinical Adoption - Apr 30th, 2026 4:00 am
Aclarion Appoints Daniel Keefe as Commercial Director, Western U.S., to Drive Continued Adoption of Nociscan - Apr 28th, 2026 4:00 am
Aclarion Announces $2.5 Million Stock Repurchase Plan - Apr 22nd, 2026 6:30 am
Aclarion Secures U.S. Patent Advancing Scalable, AI-Driven Assessment of Chronic Low Back Pain - Apr 16th, 2026 4:47 am
Aclarion Receives Pinnacle Award for AI Innovation - Apr 14th, 2026 6:00 am
Aclarion Announces Agreement with Weill Cornell Medicine - Apr 8th, 2026 6:00 am
Aclarion Highlights Growing Adoption of Nociscan at The London Clinic with New Physician Video - Apr 7th, 2026 6:00 am
Echo Lake Capital Calls for the Resignation of David Neal From the Board of Directors of Aclarion Inc. - Mar 24th, 2026 6:00 am
Aclarion, Inc. Adopts Limited Duration Stockholder Rights Plan - Mar 19th, 2026 7:25 am
Aclarion Publishes CEO Shareholder Letter Highlighting Strategic Progress and 2026 Catalysts - Mar 19th, 2026 4:00 am
Aclarion to Participate in the 38th Annual ROTH Conference, Highlighting Key 2026 Catalysts and Strong Balance Sheet - Mar 17th, 2026 4:00 am
Aclarion CEO Brent Ness to Attend LSI USA 2026 - Mar 12th, 2026 4:00 am
Aclarion Publishes 2026 Shareholder Letter from the Chairman - Feb 5th, 2026 4:00 am
Aclarion Adds High-Volume Practice, Source Healthcare, to Support Nociscan Growth and Real-World Evidence Generation - Feb 3rd, 2026 4:00 am
Aclarion Strengthens Balance Sheet and Extends Cash Runway Into 2028 - Jan 13th, 2026 4:00 am